Point72 Asia (Singapore) Pte. Ltd. Bio Atla, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 23,828 shares of BCAB stock, worth $9,769. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,828
Previous 36,899
35.42%
Holding current value
$9,769
Previous $64.9 Million
78.31%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BCAB
# of Institutions
69Shares Held
23.4MCall Options Held
30.8KPut Options Held
57K-
Anson Funds Management LP Dallas, TX4.6MShares$1.89 Million0.35% of portfolio
-
Acorn Capital Advisors, LLC New York, NY4.03MShares$1.65 Million1.29% of portfolio
-
Highbridge Capital Management LLC New York, NY2.51MShares$1.03 Million0.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$751,3150.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$563,3710.06% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $14.9M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...